Johnson & Johnson (NYSE:JNJ) Stock Position Reduced by Fiera Capital Corp
Johnson & Johnson (NYSE:JNJ) Stock Position Reduced by Fiera Capital Corp
Fiera Capital Corp cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,386,326 shares of the company's stock after selling 436,532 shares during the period. Johnson & Johnson comprises approximately 3.9% of Fiera Capital Corp's holdings, making the stock its 5th largest position. Fiera Capital Corp owned approximately 0.28% of Johnson & Johnson worth $1,085,619,000 as of its most recent SEC filing.
根据菲埃拉资本公司对美国证券交易委员会的最新披露，该公司在第三季度减持了强生(纽约证券交易所代码：JNJ-GET评级)的股份5.6%。该机构投资者在此期间出售了436,532股后，持有该公司7,386,326股股票。强生持有Fiera Capital Corp约3.9%的股份，使其成为其第五大持股。截至强生最近提交的美国证券交易委员会申请文件，菲埃拉资本持有该公司约0.28%的股份，价值1,085,619,000美元。
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Morton Brown Family Wealth LLC grew its position in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company's stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $39,000. First Bank & Trust grew its position in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company's stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Heritage Wealth Management LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $84,000. Finally, Timber Creek Capital Management LLC grew its position in Johnson & Johnson by 225.0% in the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company's stock worth $106,000 after acquiring an additional 450 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
其他机构投资者和对冲基金最近也增持或减持了该公司的股份。莫顿布朗家族财富有限责任公司第二季度增持强生股份78.0%。Morton Brown Family Wealth LLC在上个季度增持了78股后，现在持有178股该公司股票，价值3.2万美元。古德曼咨询集团(Goodman Consulting Group LLC)在第二季度购买了强生的新股份，价值约39,000美元。第一银行信托第二季度增持强生股份69.6%。First Bank&Trust在上个季度增持了156股后，现在持有380股该公司股票，价值6.7万美元。遗产财富管理有限责任公司在第二季度购买了强生的新股份，价值约84,000美元。最后，Timber Creek Capital Management LLC在第三季度将其在强生的持仓增加了225.0%。Wood Creek Capital Management LLC在上个季度增持了450股后，现在持有650股该公司股票，价值10.6万美元。67.94%的股票由对冲基金和其他机构投资者持有。
Insider Buying and Selling
内幕买卖
In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company's stock, valued at approximately $2,707,775. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock worth $40,960,735 in the last quarter. 0.35% of the stock is owned by corporate insiders.
在相关新闻中，副总裁Thibaut Munon在11月4日星期五的交易中出售了35,246股该股。这些股票的平均价格为171.18美元，总成交额为6,033,410.28美元。出售完成后，副总经理总裁现在拥有该公司40,133股，价值约6869,966.94美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在美国证券交易委员会网站。在相关新闻中，副总裁Thibaut Munon在11月4日星期五的交易中出售了35,246股该股。这些股票的平均价格为171.18美元，总成交额为6,033,410.28美元。出售完成后，副总经理总裁现在拥有该公司40,133股，价值约6869,966.94美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在美国证券交易委员会网站。此外，首席财务官罗伯特·J·德克尔在11月18日星期五的交易中出售了16,928股该股。该股以175.00美元的平均价格出售，总成交金额为2962,400.00美元。出售后，首席会计官现在拥有15,473股公司股票，价值约2,707,775美元。关于这次销售的披露可以找到这里。内部人士在上个季度出售了233,611股公司股票，价值40,960,735美元。0.35%的股份由企业内部人士持有。
Johnson & Johnson Trading Down 0.4 %
强生股价下跌0.4%
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The company had revenue of $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. During the same quarter in the prior year, the company posted $2.13 EPS. The business's revenue was down 4.4% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.52 earnings per share for the current fiscal year.
强生(纽约证券交易所代码：JNJ-GET Rating)最近一次公布季度收益数据是在1月24日，星期二。该公司公布本季度每股收益(EPS)为2.35美元，比分析师普遍预期的2.22美元高出0.13美元。强生的净利润率为18.90%，股本回报率为35.94%。该公司本季度营收为237.1亿美元，高于分析师预期的239亿美元。去年同期，该公司公布的每股收益为2.13美元。该业务的收入同比下降了4.4%。股票研究分析师平均预测，强生本财年每股收益将达到10.52欧元。
Johnson & Johnson Announces Dividend
强生宣布分红
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson's dividend payout ratio is 67.06%.
该公司最近还披露了季度股息，将于3月7日(星期二)支付。2月21日(星期二)登记在册的股东将获得1.13美元的股息。这意味着年化股息为4.52美元，股息收益率为2.69%。除息日期为2月17日星期五。强生的派息比率为67.06%.
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several research firms recently issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a "strong-buy" rating for the company. Raymond James decreased their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, October 19th. Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an "equal weight" rating and a $175.00 price objective for the company. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a "neutral" rating for the company in a report on Friday, October 14th. Finally, SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a report on Friday, January 20th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $182.75.
几家研究公司最近发布了关于JNJ的报告。斯托克新闻网在10月12日星期三的一篇报道中开始报道强生的股票。他们为该公司设定了“强力买入”评级。雷蒙德·詹姆斯在10月19日周三的一份报告中将强生的股票目标价从192.00美元下调至185.00美元，并为该公司设定了“跑赢大盘”的评级。巴克莱在10月17日星期一的一份报告中开始报道强生的股票。他们为该公司设定了“同等权重”的评级和175.00美元的目标价。10月14日，美国银行在一份报告中将强生股票的目标价从185.00美元下调至178.00美元，并将该公司的评级定为“中性”。最后，SVB Leerink在1月20日星期五的一份报告中将强生的股票目标价从194.00美元下调至186.00美元，并为该公司设定了“跑赢大盘”的评级。七位分析师对该股的评级为持有，五位分析师给出了买入评级，一位分析师对该公司股票给予了强烈的买入评级。根据MarketBeat.com的数据，强生目前的平均评级为“中等买入”，共识目标价为182.75美元。
Johnson & Johnson Profile
强生简介
(Get Rating)
(获取评级)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.
强生是一家控股公司，从事医疗保健领域产品的研发、制造和销售。它通过以下细分市场运作：消费者健康、制药和医疗设备。消费者健康部分包括用于婴儿护理、口腔护理、美容、非处方药、妇女健康和伤口护理市场的产品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取斯托克新闻网关于强生(JNJ)的研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
想看看其他对冲基金持有JNJ的是什么吗？访问HoldingsChannel.com获取强生(纽约证券交易所代码：JNJ-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
接受《强生日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对强生及相关公司的最新新闻和分析师评级的每日摘要。